De Castro N, Marcy O, Chazallon C, Messou E, et al. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial. Lancet Infect Dis 2021 Mar 2. pii: S1473-3099(20)30869.
PMID: 33667406